Merck (MRK) recently received U.S. Food and Drug Administration (FDA) approval for the use of its vaccine, Gardasil, for the protection of boys and men aged 9–26 years from genital warts related to human papillomavirus (HPV) types 6 and 11. Originally, Gardasil was approved by the FDA in June 2006, as the first vaccine for cervical cancer, (caused by HPV) for females between 9 to 26 years of age.   Earlier, in September, Gardasil received favorable recommendation from the FDA’s advisory panel. The panel voted 7-1 in favor of the vaccine’s safety and 7-0 (with one abstention) regarding its effectiveness. Apart from the favorable recommendation, the panel members expressed their concern about the lack of long-term data, which would have showed the timeframe of effectiveness of the vaccine.   The final approval of the vaccine follows the results of Merck’s phase III studies of Gardasil conducted over a period

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Friday October 16, 2009

DrStockPick.com Stock Report!

**************************************************************

Consorteum Holdings, Inc. (OTCBB: CSRH) has launched its mobile check cashing program. The introduction of this service will offer those that are currently using check cashing facilities a much more convenient way to cash their payroll checks. After two years of development with its partners, Consorteum has now proceeded to the pilot phase of its check cashing program in the Toronto, Ontario region. The first stage of the pilot implementation will be the deployment of this new service on

...

For Immediate Release

Chicago, IL – July 9, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Research In Motion (RIMM), Apple (AAPL), Palm (PALM), GlaxoSmithKline Plc (GSK) and Merck (MRK).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday’s Analyst Blog:

Apple to Grab Smartphone Share

According to a recent survey, the mobile handset manufacturing industry continues to witness increased demand for smartphones. Around 37% of the sample population already owns a smartphone, while 14.4% plans to buy the product within next 3 months.

The major benefit from this increased demand for

...

On July 7, GlaxoSmithKline Plc (GSK) announced that data from a large efficacy study showed that Cervarix, its human papillomavirus (HPV) vaccine, is highly effective in protecting against the two most common cervical cancer-causing HPV types, 16 and 18. Cervarix provided 92.9% protection against cervical pre-cancers associated with HPV 16 or 18.

HPV types 16 and 18 account for an estimated 70% of cervical cancer cases and can lead to vulvar and vaginal cancers. The study also showed that Cervarix provides cross-protection against HPV types 31, 33 and 45, which are most likely to lead to cervical cancer after 16 and 18. Results from this study, which was conducted with 18,644 women aged 15-25, were published in The Lancet.

We expect Cervarix to be a significant contributor to the company’s topline over the next several years. Cervarix is already approved in 97 countries across the world, including the

...